Seattle Genetics to present SGN-75 phase I data at ESMO Congress

Download PDF Copy

Oct 5 2010

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that preliminary data from a phase I study of SGN-75 in relapsed and refractory non-Hodgkin lymphoma and metastatic renal cell carcinoma will be presented during a poster session at the 35th European Society for Medical Oncology (ESMO) Congress being held October 8-12, 2010 in Milan, Italy. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company's proprietary technology.

“Targeting CD70 in Non-Hodgkin Lymphoma and Renal Cell Carcinoma: A Phase 1 Study of the Antibody-Drug Conjugate SGN-75”

Presentation details are as follows:

"Targeting CD70 in Non-Hodgkin Lymphoma and Renal Cell Carcinoma: A Phase 1 Study of the Antibody-Drug Conjugate SGN-75"

Monday, October 11, 2010
Poster # 532P, Hall 3
First author: Stephen M. Ansell, Mayo Clinic, Rochester, MN

Source:

: Seattle Genetics

Posted in: Drug Trial News | Medical Condition News

Tags: Antibody, Antibody-Drug Conjugate, Autoimmune Disease, B Cell, Biotechnology, Brentuximab Vedotin, Cancer, Carcinoma, Cell, Genetics, Hodgkin Lymphoma, Hodgkin's Lymphoma, Lymphoma, Monoclonal Antibody, Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Oncology, Renal Cell Carcinoma, T-Cell, Technology

Comments (0)

Download PDF Copy

Suggested Reading

Smoking before age 15 linked to higher COPD risk

Smoking before age 15 linked to higher COPD risk

AI-based tool identifies subtypes of Type 2 diabetes using glucose monitors

AI-based tool identifies subtypes of Type 2 diabetes using glucose monitors

Scientists discover new mechanism behind Huntington’s disease brain cell death

Scientists discover new mechanism behind Huntington’s disease brain cell death

New test predicts lung cancer survival better than current standards

New test predicts lung cancer survival better than current standards

Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay

Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay

New brain stem cell discovery could usher in better treatments for glioblastoma

New brain stem cell discovery could usher in better treatments for glioblastoma

Genetics, brain development, and mental health shape teen eating

Genetics, brain development, and mental health shape teen eating

AI-driven surveillance system to combat emerging infectious diseases

AI-driven surveillance system to combat emerging infectious diseases

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

World’s largest proteomics study launched by UK Biobank